Nebulization of Mesenchymal Stem Cells Secretome Attenuates Acute Respiratory Distress Syndrome Caused by SARS-CoV-2 Corona Virus: An Open-Label, Controlled Trial
The findings of this study underscore the prospective advantages and safety of the secretome of MSCs as a viable therapeutic choice in COVID-19 patients. We advise verifying our results through additional clinical trials at various disease stages.
Authors
- Maysam Yousefi (ORCID: https://orcid.org/0000-0002-1332-6670)
- Seyed Noureddin Nematollahi‐Mahani (ORCID: https://orcid.org/0000-0002-4733-1953)
- Fahimeh Pourjafari (ORCID: https://orcid.org/0000-0003-0046-5919)
- Mona Saheli (ORCID: https://orcid.org/0000-0001-7517-0117)
- Mahsa Ziasistani (ORCID: https://orcid.org/0000-0001-9312-5512)
- Masoumeh Baghalishahi (ORCID: https://orcid.org/0000-0002-2240-0262)
Institutions
- Kerman University of Medical Sciences (IR)
Publication Details
- Journal
- Advanced Biomedical Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.4103/abr.abr_477_23
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00